Crinetics Pharmaceuticals CRNX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Crinetics Pharmaceuticals (CRNX) reported accretion (amortization) of discounts and premiums, investments of $2.22M in Q1 2026.
- How has Crinetics Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Crinetics Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 49.3% year-over-year, from $4.38M to $2.22M.
- What is the long-term trend for Crinetics Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Crinetics Pharmaceuticals's accretion (amortization) of discounts and premiums, investments has grown at a 231.9% compound annual growth rate (CAGR), from -$422K to $15.43M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or the accretion of discounts on investment securities held by the company. It reflects the gradual alignment of the purchase price of a security with its face value over the holding period. Investors use this to reconcile reported net income with actual cash flows generated from investment portfolios.